---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-026749"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:39:22.492332+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Bluejay announces Symphony IL-6 Test abstract accepted for SAEM 2026 meeting

## Summary
- Abstract accepted for presentation at Society of Academic Emergency Medicine Annual Meeting, May 18-21, 2026 in Atlanta.
- Presentation reports SYMON-I pilot study data: IL-6 levels in ED linked to organ dysfunction (SOFA scores) in sepsis patients.
- Principal investigator Nathan Shapiro: IL-6 measured in ED may be associated with subsequent organ dysfunction.
- Ongoing SYMON-II pivotal study to validate IL-6 as prognostic biomarker for mortality, to support FDA 510(k) submission.
- Company developing rapid near-patient Symphony IL-6 Test for sepsis triage and monitoring.

## SEC filing metadata
- accession: 0001213900-26-026749
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000121390026026749/0001213900-26-026749-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000121390026026749/ea0281367-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-026749
- JSON: https://secwatch.observer/filing/0001213900-26-026749.json
- Plain text: https://secwatch.observer/filing/0001213900-26-026749.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.